By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™(naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a wholly-owned new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Key Statistics

Ownership: Public

Web Site: Nektar Therapeutics
Employees: 429
Symbol: NKTR

Company News
Nektar Therapeutics (NKTR) Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies 10/7/2015 6:55:58 AM
Nektar Therapeutics (NKTR) Closes Direct Private Placement With TPG Special Situations Partners Of $250 Million Of Senior Secured Notes Due In 2020 10/6/2015 8:40:20 AM
Nektar Therapeutics (NKTR) To Host Research & Development Day For Analysts And Investors On October 8th 10/1/2015 7:59:53 AM
Nektar Therapeutics (NKTR) Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models 9/22/2015 10:55:29 AM
Nektar Therapeutics (NKTR) Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG (naloxegol) Tablets In Major European Market 9/1/2015 6:43:44 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The Second Quarter Of 2015 8/6/2015 7:42:44 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2015 On Wednesday, August 5, 2015, After Close Of U.S.-Based Financial Markets 7/31/2015 8:51:39 AM
EXCLUSIVE: Nektar Therapeutics (NKTR), University of Texas MD Anderson Cancer Center Team Up on Phase 1/2 Trial of NKTR-214 6/2/2015 8:38:07 AM
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The Jefferies and Co. 2015 Global Healthcare Conference In New York City 5/28/2015 7:58:35 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The First Quarter Of 2015 5/1/2015 8:13:29 AM